spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Y-90 resin microspheres 

 HSMN NewsFeed - 25 Mar 2024
Sirtex Medical Appoints Matt Schmidt as New Chief Executive Officer and Board of Directors Member
Devices Oncology Personnel
 HSMN NewsFeed - 9 Feb 2022
Sirtex Medical and Grand Pharmaceutical Group Limited receive NDA approval of SIR-Spheres(R) Y-90 resin microspheres in China from the National Medical Products Administration
Devices Oncology Regulatory
 HSMN NewsFeed - 11 Oct 2021
Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres(R) Y-90 resin microspheres in China
Devices Oncology
 HSMN NewsFeed - 22 Mar 2021
Sirtex Medical announces new SIR-Spheres(R) DOORwaY-90 Study: The first prospective multicenter U.S.-based trial for registration as first-line treatment for hepatocellular carcinoma
Devices Oncology
 HSMN NewsFeed - 9 Dec 2020
Sirtex Medical announces strategic investment in BlackSwan Vascular, Inc.
Devices Oncology Venture Capital
 HSMN NewsFeed - 3 Jun 2020
Sirtex Medical appoints Dr. Mark A. Turco as Global Chief Medical Officer and EVP of Research & Development
Devices Oncology Personnel
 HSMN NewsFeed - 30 Jan 2018
Varian Signs Agreement to Acquire Sirtex
Devices Oncology Mergers & Acquisitions
 HSMN NewsFeed - 3 Jul 2017
New Analysis Reveals First-Line Treatment Data on SIR-Spheres(R) Y-90 Resin Microspheres for Patients with Liver Metastases from Right-Sided Primary Colon Cancer
Devices Oncology
 HSMN NewsFeed - 24 Apr 2017
SIR-Spheres(R) Y-90 Resin Microspheres Substantially Improves Quality of Survival in Primary Liver Cancer, New Study Against Standard Treatment Shows
Devices Oncology
 HSMN NewsFeed - 11 Oct 2016
New European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines Indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an Option for Post-Chemotherapy Treatment of Intrahepatic Cholangiocarcinoma (iCCA)
Devices Oncology
 HSMN NewsFeed - 25 Aug 2016
Sirtex Medical Inc. Announces 19 Percent Dose Sales Growth of SIR-Spheres(R) Y-90 resin microspheres in Fiscal Year 2016
Devices Oncology
 HSMN NewsFeed - 1 Jul 2016
Patients with Colorectal Cancer Liver Metastases Had Significantly Greater Depth of Tumour Response to SIR-Spheres(R) Y-90 resin microspheres, New SIRFLOX Analysis Shows
Devices Oncology
 HSMN NewsFeed - 31 Mar 2016
SIR-Spheres(R) Y-90 Resin Microspheres Are a Well-Tolerated Alternative to Standard Therapies for Inoperable Primary Liver Cancer, New UK NICE Medtech Innovation Briefing Says
Devices Oncology
 HSMN NewsFeed - 23 Feb 2016
SIRFLOX Study Published in Journal of Clinical Oncology
Devices Interventional Radiology Oncology
 HSMN NewsFeed - 13 Aug 2015
Sirtex Medical Inc. Announces 21.2 Percent Dose Sales Growth of SIR-Spheres(R) Y-90 resin microspheres in Fourth Quarter
Devices Oncology Interventional
 HSMN NewsFeed - 17 Mar 2015
Sirtex Reports Preliminary SIRFLOX Study Results
Devices Drug Delivery Oncology
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.